BioSante wins FDA nod for testosterone gel
The product was initially developed by BioSante and latter licensed to Teva for late stage clinical development, regulatory and marketing activities. BioSante is expected to receive royalties and
Isomorphic Labs has raised $5bn in a Series C financing round to support the development of its AI platform and advance its therapeutic candidates towards clinical evaluation.
The patent number 8,114,874 was entitled, Substituted Acetylenic Imidazo[1,2-B] Pyridazine Compounds as Kinase Inhibitors. The new patent covers both the compound itself and its pharmaceutical compositions. Additional patent